The regrowth kinetic of the surviving population is independent of acute and chronic responses to temozolomide in glioblastoma cell lines

Experimental Cell Research

Volumn 348, Issue 2, 2016, Pages 177-183

  Silva, Andrew Oliveira ^a   Dalsin, Eloisa ^a   Onzi, Giovana Ravizzoni ^a   Filippi Chiela, Eduardo Cremonese ^a,b   Lenz, Guido ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Chronic analysis; Cumulative population doubling; Glioblastoma; Surviving cells; Temozolomide

Indexed keywords

TEMOZOLOMIDE; DACARBAZINE;

ARTICLE; AUTOPHAGY; CANCER GROWTH; CANCER RECURRENCE; CELL AGING; CELL COUNT; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; KINETICS; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DACARBAZINE; GLIOBLASTOMA; HUMANS; KINETICS; MICE;

EID: 84991804311     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2016.09.014     Document Type: Article

References (35)

1. [1] Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.C., Ludwin, S.K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J.G., Eisenhauer, E., Mirimanoff, R.O., R. European Organisation for, T. Treatment of Cancer Brain, G. Radiotherapy, G. National Cancer Institute of Canada Clinical Trials, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl. J. Med. 352 (2005), 987–996.
2. [2] Ostrom, Q.T., Gittleman, H., Liao, P., Rouse, C., Chen, Y., Dowling, J., Wolinsky, Y., Kruchko, C., Barnholtz-Sloan, J., CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-Oncol., 16(Suppl 4), 2014 (iv1-63).
3. [3] Horton, T.M., Jenkins, G., Pati, D., Zhang, L., Dolan, M.E., Ribes-Zamora, A., Bertuch, A.A., Blaney, S.M., Delaney, S.L., Hegde, M., Berg, S.L., Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol. Cancer Ther. 8 (2009), 2232–2242.
4. [4] Zhang, J., Stevens, M.F., Bradshaw, T.D., Temozolomide: mechanisms of action, repair and resistance. Curr. Mol. Pharmacol. 5 (2012), 102–114.
5. [5] Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F., de Tribolet, N., Weller, M., Kros, J.M., Hainfellner, J.A., Mason, W., Mariani, L., Bromberg, J.E., Hau, P., Mirimanoff, R.O., Cairncross, J.G., Janzer, R.C., Stupp, R., MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl. J. Med. 352 (2005), 997–1003.
6. [6] Fan, C.H., Liu, W.L., Cao, H., Wen, C., Chen, L., Jiang, G., O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell death Dis., 4, 2013, e876.
7. [7] Perazzoli, G., Prados, J., Ortiz, R., Caba, O., Cabeza, L., Berdasco, M., Gonzalez, B., Melguizo, C., Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-Glycoprotein and CD133 expression. PloS One, 10, 2015, e0140131.
8. [8] Quinn, J.A., Jiang, S.X., Reardon, D.A., Desjardins, A., Vredenburgh, J.J., Rich, J.N., Gururangan, S., Friedman, A.H., Bigner, D.D., Sampson, J.H., McLendon, R.E., Herndon, J.E. 2nd, Walker, A., Friedman, H.S., Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 27 (2009), 1262–1267.
9. [9] Filippi-Chiela, E.C., Thome, M.P., Bueno e Silva, M.M., Pelegrini, A.L., Ledur, P.F., Garicochea, B., Zamin, L.L., Lenz, G., Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells. BMC Cancer, 13, 2013, 147.
10. [10] Roos, W.P., Batista, L.F., Naumann, S.C., Wick, W., Weller, M., Menck, C.F., Kaina, B., Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26 (2007), 186–197.
11. [11] Hori, Y.S., Hosoda, R., Akiyama, Y., Sebori, R., Wanibuchi, M., Mikami, T., Sugino, T., Suzuki, K., Maruyama, M., Tsukamoto, M., Mikuni, N., Horio, Y., Kuno, A., Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells. J. neuro-Oncol. 122 (2015), 11–20.
12. [12] Filippi-Chiela, E.C., Bueno e Silva, M.M., Thome, M.P., Lenz, G., Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage. Autophagy 11 (2015), 1099–1113.
13. [13] Yip, S., Miao, J., Cahill, D.P., Iafrate, A.J., Aldape, K., Nutt, C.L., Louis, D.N., MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 15 (2009), 4622–4629.
14. [14] Strik, H.M., Marosi, C., Kaina, B., Neyns, B., Temozolomide dosing regimens for glioma patients. Curr. Neurol. Neurosci. Rep. 12 (2012), 286–293.
15. [15] Godoy, P.R., Mello, S.S., Magalhaes, D.A., Donaires, F.S., Nicolucci, P., Donadi, E.A., Passos, G.A., Sakamoto-Hojo, E.T., Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines. Mutat. Res. 756 (2013), 46–55.
16. [16] Klionsky, D.J., Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8 (2012), 445–544.
17. [17] Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linskens, M., Rubelj, I., Pereira-Smith, O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92 (1995), 9363–9367.
18. [18] Filippi-Chiela, E.C., Oliveira, M.M., Jurkovski, B., Callegari-Jacques, S.M., da Silva, V.D., Lenz, G., Nuclear morphometric analysis (NMA): screening of senescence, apoptosis and nuclear irregularities. PLoS One, 7, 2012, e42522.
19. [19] Heiss, E.H., Schilder, Y.D., Dirsch, V.M., Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells. J. Biol. Chem. 282 (2007), 26759–26766.
20. [20] Silva, A.O., Felipe, K.B., Villodre, E.S., Lopez, P.L., Lenz, G., A guide for the analysis of long-term population growth in cancer. Tumour Biol., 2016.
21. [21] Darkes, M.J.M., Plosker, G.L., Jarvis, B., Temozolomide: a review of its use in the treatment of malignant gliomas, malignant melanoma and other advanced cancers. Am. J. Cancer, 1, 2002, 26.
22. [22] Yoshino, A., Ogino, A., Yachi, K., Ohta, T., Fukushima, T., Watanabe, T., Katayama, Y., Okamoto, Y., Naruse, N., Sano, E., Tsumoto, K., Gene expression profiling predicts response to temozolomide in malignant gliomas. Int. J. Oncol. 36 (2010), 1367–1377.
23. [23] Nagane, M., Asai, A., Shibui, S., Nomura, K., Kuchino, Y., Application of antisense ribonucleic acid complementary to O6-methylguanine-deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gliomas. Neurosurgery 41 (1997), 434–440 (discussion 440-431).
24. [24] Knizhnik, A.V., Roos, W.P., Nikolova, T., Quiros, S., Tomaszowski, K.H., Christmann, M., Kaina, B., Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PloS One, 8, 2013, e55665.
25. [25] Hermisson, M., Klumpp, A., Wick, W., Wischhusen, J., Nagel, G., Roos, W., Kaina, B., Weller, M., O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J. Neurochem. 96 (2006), 766–776.
26. [26] Li, S., Jiang, T., Li, G., Wang, Z., Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. Neurol. Res. 30 (2008), 567–570.
27. [27] Gomez-Manzano, C., Fueyo, J., Kyritsis, A.P., McDonnell, T.J., Steck, P.A., Levin, V.A., Yung, W.K., Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J. Natl. Cancer Inst. 89 (1997), 1036–1044.
28. [28] Senatus, P.B., Li, Y., Mandigo, C., Nichols, G., Moise, G., Mao, Y., Brown, M.D., Anderson, R.C., Parsa, A.T., Brandt-Rauf, P.W., Bruce, J.N., Fine, R.L., Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide. Mol. Cancer Ther. 5 (2006), 20–28.
29. [29] Mirzayans, R., Andrais, B., Scott, A., Murray, D., New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J. Biomed. Biotechnol., 2012, 2012, 170325.
30. [30] Koo, T., Choi, I.K., Kim, M., Lee, J.S., Oh, E., Kim, J., Yun, C.O., Negative regulation-resistant p53 variant enhances oncolytic adenoviral gene therapy. Hum. gene Ther. 23 (2012), 609–622.
31. [31] Mhaidat, N.M., Zhang, X.D., Allen, J., Avery-Kiejda, K.A., Scott, R.J., Hersey, P., Temozolomide induces senescence but not apoptosis in human melanoma cells. Br. J. Cancer 97 (2007), 1225–1233.
32. [32] Hirose, Y., Berger, M.S., Pieper, R.O., p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 61 (2001), 1957–1963.
33. [33] Kong, Y., Cui, H., Ramkumar, C., Zhang, H., Regulation of senescence in cancer and aging. J. Aging Res., 2011, 2011, 963172.
34. [34] Brigulova, K., Cervinka, M., Tosner, J., Sedlakova, I., Chemoresistance testing of human ovarian cancer cells and its in vitro model. Toxicol. Vitro 24 (2010), 2108–2115.
35. [35] Loizzi, V., Chan, J.K., Osann, K., Cappuccini, F., DiSaia, P.J., Berman, M.L., Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am. J. Obstet. Gynecol. 189 (2003), 1301–1307.